Safety of Thrombolysis in Acute Ischemic Stroke: A Review of Complications, Risk Factors, and Newer Technologies

The Neurohospitalist

Volumn 1, Issue 3, 2011, Pages 138-147

  Miller, Daniel J ^a   Simpson, Jennifer R ^a   Silver, Brian ^b,c  

^a HENRY FORD HOSPITAL   (United States)

^b RHODE ISLAND HOSPITAL   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

safety; stroke; thrombolysis

Indexed keywords

EID: 84992816467     PISSN: 19418744     EISSN: 19418752     Source Type: Journal    
DOI: 10.1177/1941875211408731     Document Type: Review

References (63)

1. Barber PA Zhang J Demchuk AM Hill MD Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001; 56(8):1015–1020.
2. Deng YZ Reeves MJ Jacobs BS, et al. IV tissue plasminogen activator use in acute stroke: experience from a statewide registry. Neurology. 2006; 66(3):306–312.
3. Del Zoppo GJ Saver JL Jauch EC Adams HP Jr. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association. Stroke. 2009; 40(8):2945–2948.
4. Kase CS Furlan AJ Wechsler LR, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke: the PROACT II trial. Neurology. 2001; 57(9):1603–1610.
5. Khatri P Hill MD Palesch YY, et al. Methodology of the Interventional Management of Stroke III Trial. Int J Stroke. 2008; 3(2):130–137.
6. Smith WS Sung G Saver J, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the Multi MERCI trial. Stroke. 2008; 39(4):1205–1212.
7. Penumbra pivotal stroke trial investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke. 2009; 40(8):2761–2768.
8. Saver JL. Hemorrhage after thrombolytic therapy for stroke: the clinically relevant number needed to harm. Stroke. 2007; 38(8):2279–2283.
9. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. Nov 1997; 28(11):2109–2118.
10. Hacke W Kaste M Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359(13):1317–1329.
11. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke. 2003; 34(12):2847–2850.
12. Mazighi M Serfaty JM Labreuche J, et al. Comparison of intravenous alteplase with a combined intravenous-endovascular approach in patients with stroke and confirmed arterial occlusion (RECANALISE study): a prospective cohort study. Lancet Neurol. 2009; 8(9):802–809.
13. Brown DL Barsan WG Lisabeth LD Gallery ME Morgenstern LB. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005; 46(1):56–60.
14. Longstreth WT Jr Katz R Tirschwell DL Cushman M Psaty BM. Intravenous tissue plasminogen activator and stroke in the elderly. Am J Emerg Med. 2010; 28(3):359–363.
15. Tanne D Kasner SE Demchuk AM, et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: the Multicenter rt-PA Stroke Survey. Circulation. 2002; 105(14):1679–1685.
16. Berrouschot J Rother J Glahn J Kucinski T Fiehler J Thomalla G. Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or =80 years) stroke patients. Stroke. 2005; 36(11):2421–2425.
17. Bluhmki E Chamorro A Davalos A, et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol. 2009; 8(12):1095–1102.
18. Wahlgren N Ahmed N Eriksson N, et al. Multivariable analysis of outcome predictors and adjustment of main outcome results to baseline data profile in randomized controlled trials: Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST). Stroke. 2008; 39(12):3316–3322.
19. Cucchiara B Kasner SE Tanne D, et al. Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke: pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II Trials. Stroke. 2009; 40(9):3067–3072.
20. Chernyshev OY Martin-Schild S Albright KC, et al. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia. Neurology. 2010; 74(17):1340–1345.
21. Demchuk AM Morgenstern LB Krieger DW, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30(1):34–39.
22. Lansberg MG Albers GW Wijman CA. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. Cerebrovasc Dis. 2007; 24(1):1–10.
23. Rodriguez-Garcia JL Botia E de La Sierra A Villanueva MA Gonzalez-Spinola J. Significance of elevated blood pressure and its management on the short-term outcome of patients with acute ischemic stroke. Am J Hypertens. 2005; 18(3):379–384.
24. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. Dec 14 1995; 333(24):1581–1587.
25. Tsivgoulis G Frey JL Flaster M, et al. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke. Nov 2009; 40(11):3631–3634.
26. Derex L Hermier M Adeleine P, et al. Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator. J Neurol Neurosurg Psychiatry. Jan 2005; 76(1):70–75.
27. Dorado L Millan M de la Ossa NP, et al. Influence of antiplatelet pre-treatment on the risk of intracranial haemorrhage in acute ischaemic stroke after intravenous thrombolysis. Eur J Neurol. Feb; 17(2):301–306.
28. Dowlatshahi D Hakim A Fang J Sharma M. Pre admission antithrombotics are associated with improved outcomes following ischaemic stroke: a cohort from the Registry of the Canadian Stroke Network. Int J Stroke. Oct 2009; 4(5):328–334.
29. Hermann A Dzialowski I Koch R Gahn G. Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? J Neurol Sci. Sep 15 2009; 284 (1-2): 155–157.
30. Patel SC Levine SR Tilley BC, et al. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA. Dec 12 2001; 286(22):2830–2838.
31. Demchuk AM Hill MD Barber PA Silver B Patel SC Levine SR. Importance of early ischemic computed tomography changes using ASPECTS in NINDS rtPA Stroke Study. Stroke. Oct 2005; 36(10):2110–2115.
32. Marler JR Tilley BC Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology. Dec 12 2000; 55(11):1649–1655.
33. Clark WM Albers GW Madden KP Hamilton S. The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators. Stroke. Apr 2000; 31(4):811–816.
34. Zinkstok S Nederkoorn P Vergouwen M. Safety of Thrombolysis in Patients with Acute Ischemic Stroke Caused by Cervical Artery Dissection-A Review. European Neurological Journal. 2010; 2(1):65–72.
35. Aries MJ Uyttenboogaart M Vroomen PC De Keyser J, Luijckx GJ. tPA treatment for acute ischaemic stroke in patients with leukoaraiosis. Eur J Neurol. Jun 1; 17(6):866–870.
36. Palumbo V Boulanger JM Hill MD Inzitari D Buchan AM. Leukoaraiosis and intracerebral hemorrhage after thrombolysis in acute stroke. Neurology. Mar 27 2007; 68(13):1020–1024.
37. Demchuk AM Khan F Hill MD, et al. Importance of leukoaraiosis on CT for tissue plasminogen activator decision making: evaluation of the NINDS rt-PA Stroke Study. Cerebrovasc Dis. 2008; 26(2):120–125.
38. Broderick J Connolly S Feldmann E, et al. Guidelines for the management of spontaneous intracerebral hemorrhage in adults: 2007 update: a guideline from the American Heart Association/American Stroke Association Stroke Council, High Blood Pressure Research Council, and the Quality of Care and Outcomes in Research Interdisciplinary Working Group. Stroke. Jun 2007; 38(6):2001–2023.
39. Morgenstern LB Hemphill JC 3rd Anderson C, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. Sep; 41(9):2108–2129.
40. Albers GW Bates VE Clark WM Bell R Verro P Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA. Mar 1 2000; 283(9):1145–1150.
41. Lopez-Yunez AM Bruno A Williams LS Yilmaz E Zurru C Biller J. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage. Stroke. Jan 2001; 32(1):12–16.
42. Adams HP Jr. del Zoppo G Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. May 2007; 38(5):1655–1711.
43. Aleu A Mellado P Lichy C Kohrmann M Schellinger PD. Hemorrhagic complications after off-label thrombolysis for ischemic stroke. Stroke. Feb 2007; 38(2):417–422.
44. Kim JT Park MS Yoon W Cho KH. Detection and Significance of Incidental Unruptured Cerebral Aneurysms in Patients Undergoing Intravenous Thrombolysis for Acute Ischemic Stroke. J Neuroimaging. Dec 9.
45. Scott PA Frederiksen SM Kalbfleisch JD, et al. Safety of intravenous thrombolytic use in four emergency departments without acute stroke teams. Acad Emerg Med. Oct; 17(10):1062–1071.
46. De Smedt A De Raedt S Nieboer K De Keyser J Brouns R. Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis. 2010; 30(5):533–534.
47. Gadhia J Starkman S Ovbiagele B Ali L Liebeskind D Saver JL, Assessment and improvement of figures to visually convey benefit and risk of stroke thrombolysis. Stroke. Feb; 41(2):300–306.
48. Lou M Safdar A Mehdiratta M, et al. The HAT Score: a simple grading scale for predicting hemorrhage after thrombolysis. Neurology. Oct 28 2008; 71(18):1417–1423.
49. Kent DM Selker HP Ruthazer R Bluhmki E Hacke W. The stroke-thrombolytic predictive instrument: a predictive instrument for intravenous thrombolysis in acute ischemic stroke. Stroke. Dec 2006; 37(12):2957–2962.
50. Rudolf J Grond M Schmulling S Neveling M Heiss W. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase. Neurology. Aug 22 2000; 55(4):599–600.
51. Hill MD Lye T Moss H, et al. Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke. Neurology. May 13 2003; 60(9):1525–1527.
52. Kidwell CS Saver JL Mattiello J, et al. Diffusion-perfusion MRI characterization of post-recanalization hyperperfusion in humans. Neurology. 2001; 57(11):2015–2021.
53. Schwamm LH Holloway RG Amarenco P, et al. A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke. Jul 2009; 40(7):2616–2634.
54. Meyer BC Raman R Hemmen T, et al. Efficacy of site-independent telemedicine in the STRokE DOC trial: a randomised, blinded, prospective study. Lancet Neurol. Sep 2008; 7(9):787–795.
55. Schellinger PD Bryan RN Caplan LR, et al. Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010; 75(2):177–185.
56. Tan JC Dillon WP Liu S Adler F Smith WS Wintermark M. Systematic comparison of perfusion-CT and CT-angiography in acute stroke patients. Ann Neurol. Jun 2007; 61(6):533–543.
57. Davis S Donnan G Parsons M, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet neurology. 2008; 7(4):299–309.
58. Albers G Thijs V Wechsler L, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Annals of neurology. 2006; 60(5):508–517.
59. Hacke W Albers G Al-Rawi Y, et al. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. Jan 2005; 36(1):66–73.
60. Furlan AJ Eyding D Albers GW, et al. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. May 2006; 37(5):1227–1231.
61. Hacke W Furlan AJ Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. Feb 2009; 8(2):141–150.
62. Barreto AD Martin-Schild S Hallevi H, et al. Thrombolytic therapy for patients who wake-up with stroke. Stroke. Mar 2009; 40(3):827–832.
63. Kang D-W Sohn S-I Yu K-H, et al. Reperfusion Therapy in Acute Ischemic Stroke with Unclear Onset by MRI Evaluation (RESTORE). Stroke. 2011; 42(3):e110.